Preclinical Toxicity of Paclitaxel Biopolymer Formulation

Ермакова, Н. П.; Бонарцев, А. П.; Zernov, A.L.; Konyaeva, O. I.; Kulbachevskaya, Natalia Y; Меркулова, И. Б.; Abramovac, Tatiana V; Chaley, V. A.; Zharkova, I. I.; Yakovlev, Sergey; Мышкина, В. Л.; Mahina, T.K.; Бонарцева, Г. А.; Шайтан, К. В.; Бухман, В. М.

doi:10.2174/1871520616666160817104529

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, paclitaxel has obvious toxicity. For example, it can cause bone marrow suppression and peripheral neuropathy ( 22 ). However, in a first-line study of non-small cell lung (NSCLC), nab-paclitaxel combined with carboplatin was used, and the results showed that the combination could reduce cytotoxicity ( 23 ).…”

Section: Paclitaxel Binding Domainmentioning

confidence: 99%

A review of research progress of antitumor drugs based on tubulin targets

Cheng¹,

Li²,

Feng³

2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Microtubules exist in all eukaryotic cells and are one of the critical components that make up the cytoskeleton. Microtubules play a crucial role in supporting cell morphology, cell division, and material transport. Tubulin modulators can promote microtubule polymerization or cause microtubule depolymerization. The modulators interfere with the mitosis of cells and inhibit cell proliferation. Tubulin mainly has three binding domains, namely, paclitaxel, vinca and colchicine binding domains, which are the best targets for the development of anticancer drugs. Currently, drugs for tumor therapy have been developed for these three domains. However, due to its narrow therapeutic window, poor selectivity, and susceptibility to drug resistance, it has severely limited clinical applications. The method of combined medication, the change of administration method, the modification of compound structure, and the research and development of new targets have all changed the side effects of tubulin drugs to a certain extent. In this review, we briefly introduce a basic overview of tubulin and the main mechanism of anti-tumor. Secondly, we focus on the application of drugs which developed based on the three domains of tubulin to various cancers in various fields. Finally, we further provide the development progress of tubulin inhibitors currently in clinical trials.

show abstract

Section: Paclitaxel Binding Domainmentioning

confidence: 99%

A review of research progress of antitumor drugs based on tubulin targets

Cheng¹,

Li²,

Feng³

2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…and chemically synthesized polymers, PHB and its copolymers are obtained biotechnologically, which allows achieving a high degree of purity, setting and controlling the physicochemical properties of biopolymers within narrow limits in the process of their biosynthesis [1]. Because PHB has biodegradable and biocompatible properties simultaneously, it has received much attention as the base component for perspective medical devices [4][5][6][7] and drug dosage formulations [8][9][10][11][12][13] as well as novel friendly environment materials including packaging applications [14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Biodegradation of Poly(3-Hydroxybutyrate) and Poly(3-Hydroxybutyrate-Co-3-Hydroxy-4-Methylvalerate) Films by Porcine Pancreatic Lipase

Жуйков

Rusakov

Усеинов

et al. 2018

KEM

View full text Add to dashboard Cite

In the current work, the degradation of poly (3-hydroxybutyrate) (PHB) and poly (3-hydroxybutyrate-co-3-hydroxy-4-methylvalerate) (PHB4MV) films was studied in vitro by pancreatic lipase. The changes in film properties were traced by several analytical methods: the change of weight, molecular weight, and Young’s modulus (by nanoindentation) were measured. During the six months of polymer films degradation the weight of samples decreased slightly, while a great increase in Young's modulus due to the relatively fast degradation of the amorphous areas was observed, as well as molecular weight of polymers decreased significantly. Weight loss of PHB4MV is faster than degradation rate of PHB, but the molecular weight of PHB 1700 decrease rapidly than PHB4MV; the Young’s modulus of polymers remained relatively unchanged.

show abstract

Preclinical Toxicity of Paclitaxel Biopolymer Formulation

Abstract: Thus, the PBF as a prolong drug needs to correct its parameters for further drug formulation development.

Cited by 2 publications

References 0 publications

A review of research progress of antitumor drugs based on tubulin targets

A review of research progress of antitumor drugs based on tubulin targets

Biodegradation of Poly(3-Hydroxybutyrate) and Poly(3-Hydroxybutyrate-Co-3-Hydroxy-4-Methylvalerate) Films by Porcine Pancreatic Lipase

Contact Info

Product

Resources

About